信立泰(002294.SZ)：泰卡西单抗注射液上市申请获得受理

Core Viewpoint - The company, Sinopharm (002294.SZ), has received acceptance for its listing application of the self-developed Class 1 biological drug "Takasimab Injection" (Project Code: SAL003) by the National Medical Products Administration [1] Group 1 - The drug Takasimab Injection is a recombinant fully human anti-PCSK9 monoclonal antibody [1] - It is intended for the treatment of hypercholesterolemia and mixed dyslipidemia [1] - The company holds independent intellectual property rights for the anti-PCSK9 monoclonal antibody [1]